In 2028, Merck faces the possible loss of market exclusivity for its biggest product, Keytruda, which accounted for nearly half of its pharmaceutical revenue over the first nine months of 2023. Aiming to maintain its market share, Merck has been developing a subcutaneous formulation and testing the drug in new combinations.
But the New Jersey-based drugmaker must also rely on new products to sustain revenue growth. That will require finding next-generation products to build on drugs like Keytruda, which turn the body’s immune system onto diseased tumor cells.
